Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

02-01-2024(Tue) 29-12-2023(Fri) 28-12-2023(Thu) 27-12-2023(Wed) 22-12-2023(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
2 Apr, 2020 (Thursday)

            
CHINARES CEMENT(1313)
Analysis¡G
China Resources Cement Holdings (1313) is exploring opportunities for the development of aggregates in the regions where it has business operation. It will fully leverage on the synergetic advantages of cement, concrete, aggregates and prefabricated construction businesses, promote industrial integrative development and further strengthen its core competitive advantages. In 2019, the Group has achieved breakthroughs in the new businesses of aggregates, prefabricated construction and engineered stones. Regarding its core cement business, the Group continuously implements lean management and promotes key projects of technological upgrade for energy saving. As of the end of 2019, the Group had completed the technological upgrade of packaging machines and dust collection systems of mobile loading machines at all cement production plants and grinding stations, which had improved measurement accuracy, reduced operating costs and further enhanced operating efficiency and economic benefits. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $8.65, Target Price: $9.50, Cut Loss Price: $8.20


HR(600276)
Analysis¡G
Hengrui Medicine is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and R & D, production and promotion of high-quality drugs. It has more than 20,000 employees worldwide. It is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China, and a national anti-tumor drug The leading unit of the Technology Innovation Industry-University-Research Alliance has a National Targeted Drug Engineering Technology Research Center and a postdoctoral research station. The company has already approved 5 innovative drugs, irenixib, apatinib, 19K, pirlotinib, and carelizumab, and has launched a batch of innovative drugs in clinical development. clinical experiments. In the development of innovative drugs, the company applies for clinical trials of innovative drugs every year. In 2019, the company`s operating income reached 23.289 billion yuan, an increase of 33.70% over the same period last year; the net profit attributable to the owners of the parent company was 5.328 billion yuan, an increase of 31.05% over the same period last year.
Strategy¡G
Buy-in Price: RMB86.00, Target Price: RMB97.00, Cut Loss Price: RMB80.00



Report Review of March. 2020

Sectors:

Air & Automobiles (Zhang Jing),

Environment (Leon Duan)

Automobile & Air (ZhangJing)

This month I released 4 updated reports of Minth (425.HK), GAC (2238.HK), Sanhua (002050.CH), and Jonjee (600872.CH), which got success by their unique Competitive edge. Among them, we highly recommend Jonjee (600872.CH).

Jonjee Hi-Tech reported revenues of RMB4675 million in 2019, an increase of 12.20% yoy; a net profit attributable to the shareholders of the listed company of RMB718 million, an increase of 18.19% yoy, and an EPS of RMB0.9 compared with an EPS of RMB0.76 last year. The result was basically in line with our expectations at the beginning of last year. The result of company's condiment sector maintained a fast growth, the annual revenue of Meiweixian in 2019 was RMB4468 million, up by 15.98% yoy, an 6% increase in growth rate compared with last year; the company reported a net profit of RMB796 million, up 27.6% yoy.

The Company mentioned the 5-Year Goal of Double Hundred, which was to reach 1 million tons of output and RMB10 billion in revenue by 2023. In order to achieve this objective, the Company has not only steadily promoted the second-phase expansion project of the Yangxi Plant, but also planned to invest RMB1275 million to upgrade and expand the Zhongshan Plant to increase the production capacity from the current 314,300 tons to 584,200 tons. It is estimated that the project will bring in a revenue increase of RMB1575 million and net profit of RMB355 million. On the other hand, channel sinking and employee incentives will be enhanced. The development rate of prefecture-level cities will be increased to 87.83%, and the development rate at district and county level will reach 46.23%. We-Media and online advertising will continue to be strengthened.

After Baoneng taking over the company, the improvement of the incentive mechanism and management efficiency will lay a foundation for the Company's long-term development. The narrowing of the gap with the first-tier companies is also expected to open up space for the company's growth.

Environment (Leon Duan)

I released update reports on CEB WATER (1857.HK). In 2019, the company recorded revenue of HKD 5.55 billion, a year-on-year increase of 16%, an increase of 2.4 percentage points from the first three quarters of 2019. The increase in revenue was mainly due to an increase of HKD 300 million in construction revenue, an increase of HKD 300 million in operating income, an increase of HKD 76 million in financial revenue, and an increase of HKD 99 million in technical services revenue, representing year-on-year growth of 11%, 25%, 10% and 98%. The above-mentioned increase in revenue was mainly due to the increase in new projects, the operation of some new projects and the increase in water prices of some projects. The company's gross profit was HKD 1.89 billion, a year-on-year increase of 17%, which was 2.1 percentage points lower than the growth rate of gross profit in the first three quarters of 2019. The gross profit margin was maintained at 34% because the revenue share of construction business (about 24% gross profit margin) and operating services (about 47% gross profit margin) was similar to the previous year. Among them, construction revenue, construction contract revenue and technical service revenue totaled approximately 58%.

Profit attributable to equity holders of the company was HKD 830 million, an increase of 23% year-on-year, and an increase of 5.9 percentage points from the first three quarters of 2019. The company's various operating indicators exceeded our expectations, reflecting the company's good project growth and cost management capabilities.

We believe that the impact of the new pneumonia epidemic on the company is relatively limited. Although the shutdown of some industrial enterprises has affected the wastewater treatment capacity of the company's industrial park, a slight increase in municipal domestic sewage offsets this impact, and the industrial wastewater treatment capacity is expected to gradually recover in the near future, and I believe that it will soon return to normal levels. In terms of construction projects, the company's resumption of work after the holiday this year has been delayed compared to previous years, but it has gradually resumed work. I believe the government's encouragement of resumption of production will gradually ease the shutdown happening. In addition, the company's liability ratio increased slightly in 2019, an increase of 2.1 percentage points from last year to 57.9%. However, the return on shareholders` equity also increased by 1.4 percentage points to 9.9%, reflecting the improvement of the company's profitability. The dividend payout ratio increased slightly by 2 percentage points to 25%. The company's management believes that there is still room for improvement in the future dividend payout ratio. In addition, the company expects capital expenditure of approximately HKD 3 billion in 2020, which will maintain approximately the same growth rate as in 2019.

Click Here for PDF format...




Writer Info
Research Department
Tel: +86 21 51699400-105
Email:
research@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]